FDA Sides With Lilly; Seeks Class Warning On Antipsychotic Diabetes Risk

The comparative risk for diabetes among atypical antipsychotics needs further research, FDA says in a letter to six manufacturers requesting a diabetes and hyperglycemia warning across the class